All 2026 dates on sale. Register before December 31!
The neurotoxin market is more crowded than ever. With six FDA‑approved options now available, you might be wondering: do I really need to add another product to my practice?
The recent U.S. launch of Letybo® (letibotulinumtoxinA‑wlbg), South Korea’s #1 neurotoxin, is making that a critical question for aesthetic providers.
But beyond its fast onset and competitive price, its clinical data reveals a compelling safety feature that could address long‑term patient outcomes.
What you will learn in this article:
While new to the U.S., Letybo® has a long track record of success internationally, where it is known as Botulax and other brand names. With over 31 million treatments administered globally across more than 65 countries, it’s a major player in the international aesthetics market.
Its FDA approval in February 2024 for the treatment of moderate to severe glabellar lines in adults was based on three Phase III trials involving more than 1,000 participants, which demonstrated its safety and efficacy.
For a detailed overview of Letybo’s FDA approval and clinical trial data, you can read the IAPAM’s initial coverage: Letybo®: A New FDA‑Approved Neurotoxin for Glabellar Lines.
Let’s break down how Letybo® compares to Botox® and the other new kid on the block, Daxxify®.
Understanding these newer products helps you make strategic decisions about your neurotoxin portfolio.
For a comprehensive comparison of all six FDA‑approved neurotoxins, see our complete neurotoxin comparison guide.
| Feature | Letybo® | Botox® | Daxxify® |
|---|---|---|---|
| Onset | 2–7 days (often visible by day 3–5) | 3–7 days | 3–7 days |
| Duration | 3–4 months | 3–4 months | 6–9 months |
| Formulation | LetibotulinumtoxinA (type A, high purity) | OnabotulinumtoxinA | DaxibotulinumtoxinA with peptide carrier |
| Diffusion | Similar to other toxins (moderate) | Moderate | Low–moderate (precision‑focused) |
| Patient Cost* | ≈ $9–$13 per unit | ≈ $10–$18 per unit | Higher per treatment than Botox |
| Best For | Faster onset, natural look, cost‑conscious patients | Gold standard, broad applications | Longest duration, fewer annual visits |
*Typical U.S. practice pricing; actual fees vary by clinic and market.
*Typical U.S. practice pricing ranges; actual fees vary by clinic and region.
Beyond the comparison chart, Letybo® has several unique characteristics that are generating buzz among providers.
“As a physician, I welcome the introduction of newer toxins with newer manufacturing processes that can deliver a highly purified product with an excellent safety profile,” Ava Shamban, MD, a board‑certified dermatologist and clinical investigator on the FDA trials for Letybo told Allure Magazine.
While Letybo® is FDA‑approved for treating moderate to severe glabellar lines (the “11s”), experienced providers are also using it for common off‑label applications.
Dosing should always be tailored to the individual, but here are some typical starting points for discussion, based on the pivotal trials and common practice patterns:
Taken together, these qualities make Letybo® a strong option for patients who want a softer, natural aesthetic, faster visible results, and better value, especially those who are newer to injectables or excited by K‑Beauty–inspired treatments.
For providers setting patient expectations, the Letybo® treatment process is straightforward and similar to other neurotoxin treatments. Here is a concise overview you can share with patients:
Early provider experiences with Letybo® highlight the importance of technique adaptation.
According to published reports and clinical commentary, while Letybo® shares similarities with Botox®, injectors note that dosing strategies and injection patterns may require adjustment to achieve optimal results.
Provider training materials emphasize that Letybo units are not interchangeable with Botox®, and practitioners report that understanding these differences is key to patient satisfaction.
From a business perspective, Letybo®’s lower price point—often estimated at roughly 10–25% less than Botox® per unit in many U.S. practices—can be a compelling advantage.
This may allow you to offer more competitive pricing to cost‑conscious patients without compromising on treatment quality, as long as you invest in patient education and marketing to build awareness for a newer brand.
When introducing a new product, patient communication is key. Here are some tips for talking to your patients about Letybo®:
For more guidance on navigating the various neurotoxin options with your patients, refer to the IAPAM’s comprehensive guide: Neurotoxins in your Aesthetic Practice.
Letybo®’s arrival in the U.S. market represents an important addition to the neurotoxin landscape, offering providers a clinically validated option with a faster onset, competitive pricing, and an exceptional immunogenicity profile.
While it shares many similarities with established products like Botox®, its unique characteristics—particularly the zero neutralizing antibody rate in clinical trials and its K-Beauty appeal—make it a strategic choice for specific patient populations.
Whether Letybo® becomes a cornerstone of your practice or a complementary option alongside Botox® and other neurotoxins will depend on your patient demographics, practice positioning, and willingness to invest in provider training and patient education.
For practices looking to differentiate themselves with cost-effective, natural-looking results and faster patient satisfaction, Letybo® deserves serious consideration.
Is Letybo® as safe as Botox®?
Yes, Letybo® underwent rigorous clinical trials to receive FDA approval and has been used safely in millions of treatments worldwide.
Are the units for Letybo® and Botox® interchangeable?
While the dosing is similar, it is crucial to follow the manufacturer’s guidelines for reconstitution and dosing. As many experienced providers note, injection techniques may need to be adjusted for optimal results.
What are the common side effects of Letybo®?
Like other neurotoxins, the most common side effects are temporary and mild, including bruising, swelling, redness at the injection site, and headache. These typically resolve within a few days.
What should I avoid after a Letybo® treatment?
To ensure the best results, patients should avoid strenuous exercise, saunas, and excessive alcohol for 24 hours. It’s also recommended to avoid lying down for at least 4 hours post‑treatment.
How does Letybo® compare to Dysport® or Xeomin®?
Letybo®’s profile is often compared to Botox®. Dysport® is known for having a wider diffusion, which can be beneficial for larger areas like the forehead, while Xeomin® is a “naked” neurotoxin without complexing proteins. For a full breakdown, see our complete neurotoxin comparison guide.
How does Letybo®’s cost compare to other neurotoxins?
Letybo® is generally priced lower than Botox, making it a cost‑effective option for both providers and patients.
Attend the most comprehensive accredited AMA PRA CAT 1 CME Botox® training weekend, learn how to create a profitable practice with the top 5 most lucrative non-invasive treatments.
Add-on GLP-1 agonists for weight loss and/or business for 4-days of comprehensive, fun CME-accredited training like none other!
Hands-on Botox® injection training is done in a clean multi-million dollar medspa, NOT in a hotel. We provide live models and product, you show up and enjoy the weekend with our expert instructors!
Scottsdale, Arizona
Save $3,605 when you become an IAPAM member and register to attend all 4-days!
References:
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!